Ets2 knockdown inhibits tumorigenesis in esophageal squamous cell carcinoma  in vivo  and  in vitro

Qinghua Li; Lu Yang; Kang Han; Liqiang Zhu; Yanting Zhang; Shanshan Ma; Kun Zhang; Bo Yang; Fangxia Guan

doi:10.18632/oncotarget.11369

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Ets2 knockdown inhibits tumorigenesis in esophageal squamous cell carcinoma in vivo and in vitro

Qinghua Li, Lu Yang, Kang Han, Liqiang Zhu, Yanting Zhang, Shanshan Ma, Kun Zhang, Bo Yang and Fangxia Guan _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:61458-61468. https://doi.org/10.18632/oncotarget.11369

Metrics: PDF 1482 views | HTML 1782 views | ?

Abstract

Qinghua Li1,2,*, Lu Yang2,*, Kang Han2,*, Liqiang Zhu3, Yanting Zhang2, Shanshan Ma2, Kun Zhang2, Bo Yang1, Fangxia Guan1,2

1The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China

2School of Life Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, China

3The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450002, Henan Province, China

*These authors contributed equally to this work

Correspondence to:

Fangxia Guan, email: [email protected]

Bo Yang, email: [email protected]

Keywords: Ets2, esophageal squamous cell carcinoma, proliferation, apoptosis, mTOR/p70S6K signaling pathway

Received: December 10, 2015 Accepted: August 08, 2016 Published: August 18, 2016

ABSTRACT

Increased expression of Ets2 is reported upregulated in esophageal squamous cell carcinoma tissue. However, the function of Ets2 in carcinogenesis of ESCC is poorly understood. Here, the rise of Ets2 was confirmed in ESCC cells and Ets2 depletion by RNA interference promotes cell apoptosis, inhibits cell proliferation, attenuates cell invasion and induces cell cycle G0/G1 arrest in vitro. Moreover, in vivo, Xenograft mouse model studies showed Ets2 knockdown inhibits tumor formation and metastasis significantly. Furthermore, Ets2 depletion inactivates the mTOR/p70S6K signaling pathway both in vitro and in vivo. Taken together, these findings strongly suggest that a critical role of Ets2 in human ESCC pathogenesis via the inactivation of the mTOR/p70S6K signaling pathway.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11369

Publication Alerts

Research Papers:

Ets2 knockdown inhibits tumorigenesis in esophageal squamous cell carcinoma in vivo and in vitro

Abstract